Drug Profile
Research programme: Ebola virus therapeutics - Immunotech
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Immunotech Laboratories
- Class Proteins
- Mechanism of Action Immunostimulants; Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ebola virus infections